ESPE Abstracts

Introduction: Continuous Glucose Monitoring Systems(CGM), including real-time(rtCGM) or intermittently Ssanned CGM(isCGM, flash technology) are evolving technologies that can help both healthcare professionals and families to improve glycaemic control in children and adolescents with diabetes mellitus. The technology offers the possibility of monitoring glucose in real time or on demand through the interstitial fluid, contributing to the improvement of glycaem...

Introduction: Disease-modifying agents, such as anti-CD3 monoclonal antibodies, have shown promising outcomes in improving the management of Type 1 Diabetes (T1D). Immunotherapy with teplizumab has delayed the onset of T1D for three years. It is been administered intravenously for 14 days in children and young people (CYP) aged > eight years already in stage 2 (multiple islet autoantibodies, abnormal glucose tolerance, usually pre-symptomatic). This treatme...